BioCryst Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

BioCryst Pharmaceuticals

03/08/2023 15:23

* BioCryst Pharmaceuticals Inc  BCRX.OQ  reported a
quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
June. The mean expectation of ten analysts for the quarter was
for a loss of 23 cents per share.
    * Revenue rose 25.9% to $82.49 million from a year ago;
analysts
expected $80.99 million. 
    * BioCryst Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 40 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * BioCryst Pharmaceuticals Inc shares had fallen by 1.3%
this
quarter and lost 39.5% so far this year.
    * The company reported a quarterly loss of $75.33 million.
    * Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 02:23 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.23          -0.24          Missed
 Mar. 31 2023      -0.30          -0.28          Beat
 Dec. 31 2022      -0.17          -0.38          Missed
 Sep. 30 2022      -0.29          -0.23          Beat